Mechanisms of Action of Interleukin-2 Superkines

免疫疗法正在成为过去30年来癌症治疗的最大突破之一，这是由于最近批准了抗体治疗剂Ipilimumab（抗CTLA 4）和Pembrolizumab（抗PD-1）。这极大地增加了对其他免疫激活模式的兴趣，无论是单一疗法，还是与抗体疗法的组合。在这里，我们建议破译的分子机制，支持一类新的免疫激活药物（IL-2超级因子）的生物学功能。

Immunotherapy is emerging as one of the largest breakthroughs in cancer therapy in the last 30 years, due to the recent approval of the antibody therapeutics Ipilimumab (anti-CTLA4) and Pembrolizumab (anti-PD-1). This has greatly increased interest in other immune activating modalities, either for monotherapy, or in combination with antibody therapy. Here we propose to decipher molecular mechanisms that underpin the biological function of a new class of immune activating drugs (IL-2 superkines).